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Introduction
Martin classified leiomyomatous lung lesions into three 
categories: (I) benign metastasizing leiomyoma (BML) in 
women; (II) metastatic leiomyoma in men and children; and 
(III) multiple pulmonary fibroleiomyomatous hamartoma (1).
BML is a rare disease in women occurring several years 
after an initial gynecological procedure (hysterectomy, or 
myomectomy), involving distant locations of metastases, 
such as lung, retroperitoneum, lymph nodes, bones, 
muscular tissue, skin, scars or central nervous system. The 
lung is the most common site of metastases. Sekine et al. 
report that leiomyomas represent 0.085% of pulmonary 
benign tumors (2). 
Metastases can appear as solitary or multiple lesions. 
Features of nodules include a specific smooth muscle 
phenotype, low proliferation, and slow growth (3). 
Lesions are also positive for estrogen receptors (ER) and 
progesterone receptors (PR), revealing the origin of the 
disease (4). The treatment of BML is, in most cases, quite 
controversial. Non-surgical treatment offers various options. 
Hormonal therapy (gonadotropin-releasing hormone 
analogues, selective ER modulators, or progesterone and 
aromatase inhibitors) with or without oophorectomy has 
been suggested in non-resectable cases (5). Nevertheless, 
non-surgical treatments still lack significant results. Primary 
treatment of BML, with the highest success rate, is surgery. 
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Abstract: Benign metastasizing leiomyoma (BML) is a rare disease in women undergoing surgery for 
uterine leiomyoma. About 100 cases have been reported in the literature, none of which describe the 
biological behavior of lesions. The authors present the case of a 36-year-old, asymptomatic woman who had 
undergone uterus extirpation seven years earlier for leiomyoma of the uterus. Routine chest radiography 
revealed multiple nodules in both lungs. Biopsy verified metastases from the original uterine leiomyoma. 
During a 41-month interval, 87 lesions were removed in seven operations, through mini-thoracotomy [four 
left-sided (42 lesions); and three right-sided (45 lesions)] by cautery resection and suturing of the parenchyma 
(n=83), or by wedge resection (n=4). In between the procedures, the patient received continuous oncological 
treatment (VIP protocol: etoposide, ifosfamide, cisplatin). Mean hospital stay was 5.14 days. Respiratory 
function tests performed after the last surgery showed near-normal results (FVC: 77%, FEV1: 64%, FEV1/
FVC: 0.83). Over time, a decrease in number of newly developed BML nodules was observed. Mean surgical 
sensitivity [rate of lesions appearing on computerized tomography (CT) and removed during each surgery] 
of the seven metastasectomies was 95% (range: 40–150%). Pathological examination of the nodules proved 
that, despite continuous oncological treatment, there were no signs of necrosis, thrombosis, or fibrosis. The 
number of mitoses within the nodules did not change. According to our surgical results and the fact that 
oncological treatment did not have a significant effect on the course of the disease, we conclude that in the 
management of multiple BML lesions, surgically removing as many lesions as possible is advised.
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Case presentation
The patient was a 36-year-old asymptomatic, non-smoking 
woman who had a hysterectomy for myoma of the uterus 
seven years earlier. Routine chest radiography and CT 
revealed 73 nodules on both sides of the lungs (Figure 1). 
C o r e  b i o p s y  w i t h  h e m a t o x y l i n - e o s i n  a n d 
immunohistochemical staining revealed a mesenchymal 
tumor with smooth muscle cell differentiation of tumor 
cells. The sample was strongly positive for smooth muscle 
actin (SMA), which is indicative of BML. 
From the diagnosis of BML until the last metastasectomy, 
continuous oncological treatment (VIP protocol: etoposide, 
ifosfamide, cisplatin) was administered. Since this was 
unsuccessful, the same oncology team decided to proceed 
with metastasectomies. Although preoperative chest CT 
revealed lesions in both lungs, the procedures were carried 
out through mini-thoracotomy (MT), instead of sternotomy. 
Surgical procedures are detailed in Table 1. During the 
metastasectomies, lesions were removed by parenchyma-
sparing cautery resection and wedge resection (procedures 
IV, V and VI). One chest drain was inserted after the 
metastasectomies. Throughout the seven hospitalizations, 
every postoperative phase was uneventful, and hospital stay 
ranged between four and six days (mean, 5.14 days). During 
the first operation (I), we removed 31 lesions from the right 
lung, and three months later, 36 lesions from the left lung 
(II) (see Figure 2). Despite oncological treatment, bilateral 
multiple recurrences were revealed on CT scan, and repeat 
metastasectomies were performed to remove most of these 
lesions. During each procedure, we measured surgical 
sensitivity (SS), and later calculated mean surgical sensitivity 
(mSS). SS was defined as the rate of surgically removed and 
CT-diagnosed metastases in each individual surgery, and 
mSS was the mean of the SS results of the seven procedures.
We could count the number of recurrences of lesions, 
measure their size, and observe their growth dynamics 
in a given time period owing to scheduled operations 
and controlled CTs verifying the results of oncological 
treatment. To measure the growth of the nodules, in 
relation to elapsed time, we chose two different time 
periods. Nodules in both lungs were compared. All 
Table 1 Features of surgical procedures with calculated surgical sensitivity (SS) and hospital stay
Procedures
t (months from the first 
surgery)
m1 (number 
of metastases 
revealed by CT)
m2 (number 
of metastases 
removed surgically)
*SS
Type of 
resection
Side
Days of 
hospital stay
I 0 36 31 86.1% E** R 6
II 3 37 36 97.2% E L 6
III 15 5 2 40% E L 5
IV 24 10 11 110%; mean: 97.7% E + W§ R 6
V 26 2 2 100% E + W L 5
VI 35 2 2 100% W L 4
VII 41 2 3 150% E R 4
In some cases it is difficult to find a small lesion in the depth of the parenchyma, or even on the surface of an already operated and scarry 
lung. In order to verify surgical sensitivity, the number of lesions appearing on CT slides and the number of lesions found and removed 
during the metastasectomies were compared. During the 7 metastasectomies, our surgical sensitivity ranged between 40% and 150% 
(mean: 95%). Taking those procedures into consideration, in which the number of diagnosed/removed nodules were more than 10 (in 
procedures: I, II and IV), mean SS showed to be: 97.7%. *, SS, rate of surgically removed and CT diagnosed metastases regarding the 
same surgery; **, enucleation (cautery resection); §, wedge resection. SS, surgical sensitivity; L, left; R, right. 
Figure 1 Chest X-ray performed before the first operation, 
showing multiple lesions in both lungs. 
E674 Ottlakan et al. Biological behavior: pulm BML
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2016;8(8):E672-E676jtd.amegroups.com
Figure 2 Nodules removed during the second surgery (n=36). Difference in the size of well-shaped nodules is apparent. 
visible tumors were measured in millimeters (mm). The 
percentages of nodule size development and mean values 
are shown in Table 2, and the 100-day normalized growth 
ratio is also represented. 
We used two time phases (162 and 493 elapsed days from 
first appearance of lung nodules) and measured the size of 
the same nodules on chest CT in each phase (Table 2). 
Seven months after the last procedure, spirometry results 
of the patient were as follows: FVC 77%; FEV1 64%; 
FEV1/FVC 0.83. Mean hospital stay was 5.14 days (range, 
4–6 days).
Histological examination confirmed all nodules were 
benign, with smooth muscle characteristics, originating 
from the uter ine le iomyoma.  Fluorescent  in  s i tu 
hybridization confirmed the presence of a 19q 22q terminal 
deletion, which is pathognomonic for BML. 
Chest CT performed 1.5 years after the last procedure 
showed an unverified 5-mm solitary nodule in the right 
lower lobe. 
Results
The mSS during the seven procedures was 95% (40–150%). 
During procedures in which over ten nodules were present 
on chest CT or removed surgically (procedures I, II and IV, 
see Table 1), mSS was 97.7%. 
During the first period (elapsed days: 162), the mean 
change in nodule size was 23.165%, whereas during the 
second period (elapsed days: 493) the mean value decreased 
to 10.5%. The 100-day normalized growth ratio in the two 
periods was 14% versus 2.1%. According to our results, the 
speed of nodule enlargement was significantly slower with 
elapsed time (P=0.023). 
Statistical analysis 
For comparison, a t-test and one-way analysis of variance 
were used. Categorical data were analyzed by using Fisher’s 
exact test. SPSS version 15.0 (© 2007 SPSS Inc.) was used 
for statistical analysis.
Discussion
The pathogenesis of BML is not yet clear. Theories include 
the following: (I) hormone-sensitive in situ proliferation of 
smooth muscle bundles; (II) benign smooth muscle cells 
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transported from a uterine leiomyoma and colonized in the 
lung or metastasis of a low-grade uterine leiomyosarcoma 
to the lung; and (III) surgically-induced mechanical 
displacement from a preexisting uterine tumor. 
In our unusual case, 87 nodules were removed either 
by cautery resection (n=83; 95%) or wedge resection (n=4; 
5%), in seven procedures. After these surgeries, the patient 
remained asymptomatic, continued with her job, and had 
a near-normal FEV1 (64%). Her physical status and the 
excellent postoperative results were achieved only with 
parenchyma-sparing metastasectomies. 
A challenge of a repeat metastasectomy is finding smaller 
lesions in the lung parenchyma. SS results show that repeat 
metastasectomy is a feasible and effective procedure in cases 
of BML. Regarding the growth dynamics of recurrent lesions, 
we found that tumors grew faster initially, and the number of 
recurrent lesions decreased with elapsed time (P=0.023). 
Effectiveness of oncological treatment was assessed 
based on whether necrosis occurred in the tumor after 
chemotherapy. In our case, pathological examination of the 
removed nodules showed no signs of necrosis, thrombosis, or 
fibrosis. Thus, it can be stated that in our case, chemotherapy 
did not have a significant influence on the course of the 
disease. This unsuccessful oncological treatment resulted in 
the decision to surgically remove as many lesions as possible, 
even with repeated metastasectomies. 
Based on the reduced number of recurrent lesions with 
elapsed time and their decreasing enlargement tendency, 
our results support the theory that metastases in BML are 
surgically induced mechanical displacements of a preexisting 
uterine tumor and not newly formed lesions. Based on 
our results, it can be concluded that surgery is still the 
most effective choice of treatment of BML, and repeated 
parenchyma-sparing cautery resection is a safe and effective 
method with excellent patient tolerance—even in cases with 
an extreme number of BML nodules (n=87). 
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Table 2 Difference in nodule size with elapsed time
Time of first and  
second CT
Interval between 
first and second 
CT (days)
Size of  
nodule on first  
CT (mm)
Size of the same 
nodule on second 
CT (mm)
Difference in 
diameter (mm)
Difference in size 
2011.03.28–2011.09.06 
(1st period)
162 9.1 10.6 1.5 16.48%
21.7 22.7 1.0 4.60%
7.6 12.1 4.5 59.21%
14.1 19.5 5.4 38.29%
11.5 12.3 0.8 6.95%
13.0 19.3 6.3 48.46%; mean 23.165%; 14%/100 days
2011.10.17–2013.02.21 
(2nd period)
493 6.7 6.8 0.1 1.49%
7.9 8.7 0.8 10.12%
8.1 9.6 1.5 18.51%
9.3 10.5 1.2 12.90%
6.7 7.5 0.8 11.94%
4.9 5.3 0.4 8.16%; mean: 10.5%; 2.1%/100 days
Due to scheduled operations and controlled CTs verifying the results of the oncological treatment, we were able to count the number 
of recurrences and measure their size and observe the growth dynamics of the same lesion in a given time period. For measurement of 
nodules in terms of change in size in connection with elapsed time, we choose two different time periods. Nodules in both lungs were 
compared. All visible tumors were measured and given in millimeters. Percentage of nodule development and mean values are shown. 
The 100-day normalized growth ratio in both periods is also represented. According to our results, the speed of nodule enlargement is 
significantly slower with elapsed time (P=0.023). 
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from the patient for publication of this manuscript and any 
accompanying images.
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